LENZ Therapeutics Inc
LENZ27.230USD
0.000
收盤 11/03, 16:00（美東）報價延遲15分鐘
776.06M總市值
虧損本益比TTM
關於 LENZ Therapeutics Inc 公司
LENZ Therapeutics, Inc. 是一家處於臨牀後期的生物製藥公司。該公司專注於開發首款基於乙酰克利定的眼藥水，以改善被診斷爲老花眼的患者的視力。其候選產品 LNZ100 和 LNZ101 是不含防腐劑的一次性眼藥水，每日使用一次，分別含有乙酰克利定和乙酰克利定加布林莫尼定。LNZ100 和 LNZ101 正在註冊授權 III 期 CLARITY 試驗中進行臨牀評估，作爲治療老花眼的潛在療法，老花眼影響着全球約 18 億人和美國 1.28 億人。
LENZ Therapeutics Inc簡介
公司代碼LENZ
公司名稱LENZ Therapeutics Inc
上市日期Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
員工數量42
證券類型Ordinary Share
年結日Jun 25
公司地址- -
城市- -
上市交易所NASDAQ Global Select Consolidated
國家- -
郵編- -
電話- -
網址- -
公司代碼LENZ
上市日期Jun 25, 2021
CEOMr. Evert (Eef) Schimmelpennink
LENZ Therapeutics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
620.60K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
620.60K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
99.60K
--
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
+42.00%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
3.19K
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
收入明細
暫無數據
暫無數據
業務
地區
暫無數據
股東統計
更新時間: 8月24日 週日
更新時間: 8月24日 週日
持股股東
股東類型
持股股東
持股股東
佔比
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
10.10%
Ridgeback Capital Management, L.P.
6.84%
Paradigm BioCapital Advisors LP
6.02%
其他
49.72%
持股股東
持股股東
佔比
RA Capital Management, LP
14.65%
Alpha Wave Global, LP
12.66%
Versant Ventures
10.10%
Ridgeback Capital Management, L.P.
6.84%
Paradigm BioCapital Advisors LP
6.02%
其他
49.72%
股東類型
持股股東
佔比
Venture Capital
38.62%
Hedge Fund
27.55%
Investment Advisor
23.95%
Investment Advisor/Hedge Fund
14.32%
Individual Investor
2.73%
Research Firm
2.25%
Bank and Trust
0.14%
Pension Fund
0.06%
Insurance Company
0.02%
機構持股
更新時間: 10月5日 週日
更新時間: 10月5日 週日
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
261
30.52M
107.02%
+1.08M
2025Q2
245
29.52M
104.44%
-639.13K
2025Q1
245
28.95M
104.22%
-285.84K
2024Q4
225
27.65M
100.55%
-350.42K
2024Q3
204
26.43M
96.17%
-1.73M
2024Q2
197
25.06M
103.06%
+4.18M
2024Q1
204
22.41M
93.92%
+12.70M
2023Q4
200
7.73M
92.24%
-2.14M
2023Q3
200
7.54M
90.13%
-2.49M
2023Q2
212
7.64M
91.96%
-2.29M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
RA Capital Management, LP
4.18M
14.65%
--
--
Jun 30, 2025
Alpha Wave Global, LP
3.61M
12.66%
--
--
Jun 30, 2025
Versant Ventures
2.88M
10.1%
-135.30K
-4.48%
Sep 18, 2025
Ridgeback Capital Management, L.P.
1.95M
6.84%
--
--
Apr 14, 2025
Paradigm BioCapital Advisors LP
1.72M
6.02%
+297.23K
+20.93%
Jun 30, 2025
The Vanguard Group, Inc.
1.29M
4.52%
+91.53K
+7.65%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
1.27M
4.44%
+216.45K
+20.60%
Jun 30, 2025
Adage Capital Management, L.P.
1.12M
3.94%
+585.00K
+108.79%
Jun 30, 2025
72 Investment Holdings, LLC
1.02M
3.57%
--
--
Jun 30, 2025
Sectoral Asset Management Inc.
977.25K
3.43%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 11月2日 週日
更新時間: 11月2日 週日
機構名稱
佔比
SPDR S&P Pharmaceuticals ETF
1.7%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.28%
Virtus LifeSci Biotech Clinical Trials ETF
1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
0.43%
iShares U.S. Pharmaceuticals ETF
0.34%
iShares Micro-Cap ETF
0.16%
Invesco Nasdaq Biotechnology ETF
0.14%
ProShares Ultra Nasdaq Biotechnology
0.14%
iShares Biotechnology ETF
0.11%
查看更多
SPDR S&P Pharmaceuticals ETF
佔比1.7%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
佔比1.28%
Virtus LifeSci Biotech Clinical Trials ETF
佔比1.14%
Invesco Dorsey Wright Healthcare Momentum ETF
佔比0.75%
Invesco Dorsey Wright SmallCap Momentum ETF
佔比0.43%
iShares U.S. Pharmaceuticals ETF
佔比0.34%
iShares Micro-Cap ETF
佔比0.16%
Invesco Nasdaq Biotechnology ETF
佔比0.14%
ProShares Ultra Nasdaq Biotechnology
佔比0.14%
iShares Biotechnology ETF
佔比0.11%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
公告日期
類型
比率
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
Mar 19, 2024
Merger
7→1
